Page 80 - Read Online

Lue et al. J Cancer Metastasis Treat 2022;8:11 https://dx.doi.org/10.20517/2394-4722.2021.193 Page 23 of 25

110. Love C, Sun Z, Jima D, et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 2012;44:1321-5. DOI PubMed
PMC
111. Visser HP, Gunster MJ, Kluin-Nelemans HC, et al. The polycomb group protein EZH2 is upregulated in proliferating, cultured
human mantle cell lymphoma. British journal of haematology 2001;112(4):950-8. (In eng). DOI PubMed
112. Eckerle S, Brune V, Döring C, et al. Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights
into its cellular origin, pathogenesis and relation to Hodgkin lymphoma. Leukemia 2009;23:2129-38. DOI PubMed
113. Sasaki D, Imaizumi Y, Hasegawa H, et al. Overexpression of enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone
H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy. Haematologica 2011;96:712-9. DOI PubMed PMC
114. Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer.
Nature 2002;419:624-9. DOI PubMed
115. Wagener N, Macher-Goeppinger S, Pritsch M, et al. Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic
factor in renal cell carcinoma. BMC Cancer 2010;10:524. DOI PubMed PMC
116. Kleer CG, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast
epithelial cells. Proc Natl Acad Sci U S A 2003;100:11606-11. DOI PubMed PMC
117. Garapaty-Rao S, Nasveschuk C, Gagnon A, et al. Identification of EZH2 and EZH1 small molecule inhibitors with selective impact
on diffuse large B cell lymphoma cell growth. Chem Biol 2013;20:1329-39. DOI PubMed
118. Knutson SK, Kawano S, Minoshima Y, et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-
mutant non-Hodgkin lymphoma. Mol Cancer Ther 2014;13:842-54. DOI PubMed
119. Qi W, Chan H, Teng L, et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl
Acad Sci U S A 2012;109:21360-5. DOI PubMed PMC
120. Italiano A, Soria J, Toulmonde M, et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma
and advanced solid tumours: a first-in-human, open-label, phase 1 study. The Lancet Oncology 2018;19:649-59. DOI PubMed
121. Morschhauser F, Tilly H, Chaidos A, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label,
single-arm, multicentre, phase 2 trial. The Lancet Oncology 2020;21:1433-42. DOI PubMed PMC
122. Sarkozy C, Morschhauser F, Dubois S, et al. A LYSA phase IB study of tazemetostat (EPZ-6438) plus R-CHOP in PATIENTS with
newly diagnosed diffuse large B-Cell lymphoma (DLBCL) with poor prognosis features. Clin Cancer Res 2020;26:3145-53. DOI
PubMed
123. Morishima S, Ishitsuka K, Izutsu K, et al. First-in-human study of the EZH1/2 dual Inhibitor valemetostat in relapsed or refractory
non-Hodgkin lymphoma (NHL) - updated results focusing on adult T-cell leukemia-lymphoma (ATL). Blood 2019;134:4025. DOI
124. Pasqualucci L, Dominguez-Sola D, Chiarenza A, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature
2011;471:189-95. DOI PubMed PMC
125. Andersen CL, Asmar F, Klausen T, Hasselbalch H, Grønbæk K. Somatic mutations of the CREBBP and EP300 genes affect response
to histone deacetylase inhibition in malignant DLBCL clones. Leuk Res Rep 2012;2:1-3. DOI PubMed PMC
126. Zaja F, Salvi F, Rossi M, et al. Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and
correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi. Leuk Lymphoma 2018;59:2904-10. DOI
PubMed
127. Younes A, Berdeja JG, Patel MR, et al. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor
of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1
trial. The Lancet Oncology 2016;17:622-31. DOI PubMed PMC
128. Oki Y, Kelly KR, Flinn I, et al. CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-
alterations: results from an expanded phase I trial. Haematologica 2017;102:1923-30. DOI PubMed PMC
129. Landsburg DJ, Ramchandren R, Lugtenburg PJ, et al. A pooled analysis of relapsed/refractory diffuse large B-Cell lymphoma
patients treated with the dual PI3K and HDAC inhibitor fimepinostat (CUDC-907), including patients with MYC-Altered Disease.
Blood 2018;132:4184. DOI
130. Lovén J, Hoke HA, Lin CY, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013;153:320-34.
DOI PubMed PMC
131. Cinar M, Rosenfelt F, Rokhsar S, et al. Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for
double hit and triple hit B-cell lymphomas. Leuk Res 2015;39:730-8. DOI PubMed
132. Esteve-Arenys A, Valero JG, Chamorro-Jorganes A, et al. The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-
199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma. Oncogene
2018;37:1830-44. DOI PubMed
133. Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with
rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012;30:3452-9. DOI PubMed PMC
134. Davids MS, Roberts AW, Seymour JF, et al. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory
Non-Hodgkin Lymphoma. J Clin Oncol 2017;35:826-33. DOI PMC
135. Zelenetz AD, Salles G, Mason KD, et al. Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI
phase 1b trial. Blood 2019;133:1964-76. DOI PubMed PMC
136. Rutherford SC, Abramson JS, Bartlett NL, et al. Phase I study of the Bcl-2 inhibitor venetoclax with DA-EPOCH-R as initial therapy
for aggressive B-cell lymphomas. JCO 2020;38:8003-8003. DOI